POS0630 EXPLORING THE INFLUENCE OF UNILATERAL VS. BILATERAL KNEE OSTEOARTHRITIS ON STRUCTURAL KNEE OUTCOMES: DOES DISEASE BURDEN AFFECT PROGRESSION
Notice bibliographique
Résumé
Background: While assessing symptomatic and structural outcomes in knee osteoarthritis (KOA) is common, the distinction between unilateral and bilateral KOA is less explored. Because pain reporting by subjects with bilateral KOA may be confounding for pain reports of a single joint, some newer trials choose to impose restrictions for the symptoms of the non-target knee [1-3]. The presence of multi-joint OA may reflect a more systemically driven and possibly more progressive OA phenotype that could be differing from single-joint disease. In organ diseases such as those affecting the heart, lungs, and kidneys, organ damage is the most critical parameter for function decline and mortality. Intuitively, this concept might also apply to OA, where generalized disease severity could relate to progression. However, details of differences between uni- or bilateral OA patients in terms of their typical baseline characteristics and longitudinal outcomes are not well described. Objectives: The primary goal of this analysis is to explore differences in baseline demographics and structural progression risks between unilateral and bilateral KOA. Methods: The current data is based on a post-hoc analysis of two phase III, randomized, double-blind, placebo-controlled studies where a total of 2206 participants were randomized 1:1 to oral salmon-calcitonin (0.8 mg twice daily) or placebo and followed for 24 months. For this post-hoc analysis we grouped participants into unilateral KOA or bilateral KOA based on radiological and symptomatic criteria, where KOA was defined as Kellgren-Lawrence (KL)-grade ≥2 and baseline Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain ≥30 out of 100. As per trial inclusion criteria, all participants had radiographic and symptomatic KOA of the target knee. Baseline demographics were summarized and tested with two-sample t-test for quantitative data and Fisher's exact test for categorical data. Risk for target-knee structural progression in KL-grade and joint space width (JSW) as change from baseline to year 2 were analyzed using risk ratio and ANCOVA. Correction for multiple testing was done with Bonferroni-Holm. Results: KL grade (and WOMAC pain) was obtained for 2184 (2119) participants at randomization, and 1473 (1441) participants at end of study. For baseline demographics see Table 1. This analysis identified several significant differences in baseline demographics between participants with unilateral and bilateral KOA. Participants with bilateral KOA were more likely to be female, older, have a higher BMI, and have greater target knee baseline pain compared to those with unilateral KOA. There were no differences in race and target knee baseline KL-grade. There were no differences in structural knee progression as measured with KL-grade or JSW between participants with unilateral and bilateral KOA. See Table 2. Conclusion: We found that patients with bilateral KOA were more likely to be female, older, have a higher BMI, possibly suggesting a more generalized OA, that also was associated with greater target knee baseline pain compared to those with unilateral KOA. There were no observed differences in terms of risk of structural progression based on uni- or bilateral KOA, which suggest that the general KOA disease activity is not higher in patients with more affected knee joints. REFERENCES: [1] Riddle DL, Stratford PW. Unilateral vs bilateral symptomatic knee osteoarthritis: associations between pain intensity and function. Rheumatology. 2013 Dec 1;52(12):2229–37. [2] Yazici Y, McAlindon TE, Gibofsky A, Lane NE, Clauw D, Jones M, et al. Lorecivivint, a Novel Intraarticular CDC‐like Kinase 2 and Dual‐Specificity Tyrosine Phosphorylation‐Regulated Kinase 1A Inhibitor and Wnt Pathway Modulator for the Treatment of Knee Osteoarthritis: A Phase II Randomized Trial. Arthritis & Rheumatology. 2020 Oct 6;72(10):1694–706. [3] Bihlet AR, Byrjalsen I, Andersen JR, Öberg F, Herder C, Bowes MA, et al. Symptomatic and structural benefit of cathepsin K inhibition by MIV-711 in a subgroup with unilateral pain: post-hoc analysis of a randomised phase 2a clinical trial. Clin Exp Rheumatol. 2022 May;40(5):1034–7. Table 1Baseline Demographics.Unilateral KOA(n=1112)Bilateral KOA(n=1007)Adjusted p-valueSexFemale, n (%)682 (61.3)694 (68.9)0.002Age (years)Mean (SD)63.8 (6.56)65.0 (7.03)<0.001RaceWhite, n (%)995 (89.5)862 (85.6)Asian, n (%)109 (9.8)139 (13.8)Black, n (%)6 (0.5)5 (0.5)Other, n (%)2 (0.2)1 (0.1)0.12BMI (kg/m2)Mean (SD)28.6 (4.7)29.3 (5.13)0.006Kellgren-Lawrence grade, target knee baseline2, n (%)948 (85.3)825 (81.9)3, n (%)164 (14.7)182 (18.1)0.16WOMAC pain (normalized 0-100), target knee baselineMean (SD)46.0 (13.9)51.0 (15.1)<0.001KOA defined as knee KL score ≥2 and WOMAC pain score ≥30 out of 100 Table 2Structural progression.Unilateral KOA(n=742)Bilateral KOA(n=699)Estimate95% CIAdjusted p-valueKellgren-Lawrence grade change, target knee baseline to year 2Progression, n (%)60 (8.1)64 (9.2)Risk difference (%)-1.1-4.0; 1.8Risk ratio0.880.63; 1.24Joint space width change, target knee baseline to year 2 (mm)Mean (SD)-0.31 (0.65)-0.29 (0.67)Unadjusted0.03-0.04; 0.10p=1Adjusted (sex, age, BMI, baseline WOMAC)0.03-0.04; 0.10p=1KOA defined as knee KL score ≥2 and WOMAC pain score ≥30 out of 100 Acknowledgements: NIL . Disclosure of Interests: Jakob Mejdahl Bentin: None declared, Morten Karsdal Nordic Bioscience, Nordic Bioscience, Asger R. Bihlet: None declared. © The Authors 2025. This abstract is an open access article published in Annals of Rheumatic Diseases under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Neither EULAR nor the publisher make any representation as to the accuracy of the content. The authors are solely responsible for the content in their abstract including accuracy of the facts, statements, results, conclusion, citing resources etc.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction machine sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.
Scores du classifieur distillé par catégorie (deux têtes)
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,010 | 0,012 |
| Méta-épidémiologie (sens strict) | 0,001 | 0,000 |
| Méta-épidémiologie (sens large) | 0,002 | 0,004 |
| Bibliométrie | 0,000 | 0,001 |
| Études des sciences et des technologies | 0,000 | 0,001 |
| Communication savante | 0,001 | 0,001 |
| Science ouverte | 0,001 | 0,001 |
| Intégrité de la recherche | 0,002 | 0,003 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,025 | 0,003 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».